Introduction Executive Summary Bullous pemphigoid: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Bullous pemphigoid – DelveInsight’s Analytical Perspective Late Stage Products (Phase III) • Comparative Analysis Benralizumab: AstraZeneca • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis Lazucirnon : Alkahest • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis Sutimlimab: Bioverativ • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Bullous pemphigoid Key Companies Bullous pemphigoid Key Products Bullous pemphigoid- Unmet Needs Bullous pemphigoid- Market Drivers and Barriers Bullous pemphigoid- Future Perspectives and Conclusion Bullous pemphigoid Analyst Views Bullous pemphigoid Key Companies Appendix

Table 1 Total Products for Bullous pemphigoid Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• AstraZeneca • Regeneron • Alkahest • Akari Therapeutics • Immune Pharmaceuticals • Eli Lilly and Company • Amgen • TWi Biotechnology